Enhancing mesenchymal stem cell survival and homing capability to improve cell engraftment efficacy for liver diseases

Although mesenchymal stem cell (MSC) transplantation provides an alternative strategy for end-stage liver disease (ESLD), further widespread application of MSC therapy is limited owing to low cell engraftment efficiency. Improving cell engraftment efficiency plays a critical role in enhancing MSC th...

Full description

Saved in:
Bibliographic Details
Published inStem cell research & therapy Vol. 14; no. 1; pp. 1 - 14
Main Authors Yu, Shaoxiong, Yu, Saihua, Liu, Haiyan, Liao, Naishun, Liu, Xiaolong
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 04.09.2023
BioMed Central
BMC
Subjects
Antigens
Cell survival
Cells
Chemokines
Clinical trials
Controlled conditions
Cytokines
Efficiency
Engraftment efficiency
Genetically modified organisms
Health aspects
Hepatocytes
Hypoxia
Ligands
Liver cirrhosis
Liver diseases
Mesenchymal stem cells
MSC homing
Review
Splenectomy
Stem cell transplantation
Stem cells
Transplantation
Transplants & implants
Umbilical cord
Online AccessGet full text

Cover

More Information
Summary:Although mesenchymal stem cell (MSC) transplantation provides an alternative strategy for end-stage liver disease (ESLD), further widespread application of MSC therapy is limited owing to low cell engraftment efficiency. Improving cell engraftment efficiency plays a critical role in enhancing MSC therapy for liver diseases. In this review, we summarize the current status and challenges of MSC transplantation for ESLD. We also outline the complicated cell-homing process and highlight how low cell engraftment efficiency is closely related to huge differences in extracellular conditions involved in MSC homing journeys ranging from constant, controlled conditions in vitro to variable and challenging conditions in vivo. Improving cell survival and homing capabilities enhances MSC engraftment efficacy. Therefore, we summarize the current strategies, including hypoxic priming, drug pretreatment, gene modification, and cytokine pretreatment, as well as splenectomy and local irradiation, used to improve MSC survival and homing capability, and enhance cell engraftment and therapeutic efficiency of MSC therapy. We hope that this review will provide new insights into enhancing the efficiency of MSC engraftment in liver diseases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1757-6512
1757-6512
DOI:10.1186/s13287-023-03476-4